(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.52%) $78.52
(1.31%) $2.17
(-0.03%) $2 307.80
(0.12%) $26.72
(-0.50%) $960.45
(0.04%) $0.929
(-0.10%) $10.86
(0.01%) $0.797
(0.00%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs)...
Stats | |
---|---|
Today's Volume | 39 361.00 |
Average Volume | 98 636.00 |
Market Cap | 126.23M |
EPS | $0.280 ( 2024-04-03 ) |
Next earnings date | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.99 |
ATR14 | $0.0350 (0.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-22 | Lee Ann | Buy | 1 000 | Common Stock, par value $0.0001 per share |
2024-01-31 | Grossman Fred | Buy | 81 819 | Stock Option (right to buy) |
2024-01-31 | Grossman Fred | Buy | 74 069 | Stock Option (right to buy) |
2024-01-31 | Snyder David S | Buy | 81 819 | Stock Option (right to buy) |
2024-01-31 | Berman Howard | Buy | 189 680 | Stock Option (right to buy) |
INSIDER POWER |
---|
87.36 |
Last 39 transactions |
Buy: 1 037 435 | Sell: 190 798 |
Volume Correlation
Coya Therapeutics, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Coya Therapeutics, Inc. Correlation - Currency/Commodity
Coya Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $6.00M |
Gross Profit: | $5.97M (99.54 %) |
EPS: | $-0.790 |
FY | 2023 |
Revenue: | $6.00M |
Gross Profit: | $5.97M (99.54 %) |
EPS: | $-0.790 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-27 361.00 (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.260 |
Financial Reports:
No articles found.
Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators